Cell line name |
IGROV(CDDP) |
Synonyms |
IGROVCDDP |
Accession |
CVCL_C1M7 |
Resource Identification Initiative |
To cite this cell line use: IGROV(CDDP) (RRID:CVCL_C1M7) |
Comments |
Population: Caucasian. Doubling time: 26 hours (PubMed=9488600). Selected for resistance to: ChEBI; CHEBI:27899; Cisplatin (CDDP). Derived from site: In situ; Ovary; UBERON=UBERON_0000992. |
Sequence variations |
- Mutation; HGNC; 1100; BRCA1; Simple; p.Lys654Serfs*47 (c.1961delA); ClinVar=VCV000037438; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 1101; BRCA2; Simple; p.Lys1108Argfs*11 (c.3323delA) (p.Gln1107fs) (c.3320delA); ClinVar=VCV000225716; Zygosity=Unspecified (from parent cell line).
- Mutation; HGNC; 8975; PIK3CA; Simple; p.Arg38Cys (c.112C>T); ClinVar=VCV000376493; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 8975; PIK3CA; Simple; p.Ter1069TrpinsLysAspAsn (c.3207A>G); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 9588; PTEN; Simple; p.Thr319fs*1 (c.955_958delACTT) (p.VL317fs) (V317fs*3); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 9884; RB1; Simple; p.Val654Cysfs*4 (c.1959delA); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 6770; SMAD4; Simple; p.Gly231Alafs*10 (c.692delG); ClinVar=VCV001756201; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 6770; SMAD4; Simple; p.Leu495Pro (c.1484T>C); Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 11998; TP53; Simple; p.Ser90Leufs*59 (c.267dupC) (c.267_268insC); ClinVar=VCV000634762; Zygosity=Heterozygous (from parent cell line).
- Mutation; HGNC; 11998; TP53; Simple; p.Tyr126Cys (c.377A>G); ClinVar=VCV000458541; Zygosity=Heterozygous (from parent cell line).
|
Disease |
Ovarian endometrioid adenocarcinoma (NCIt: C7979) Endometrioid carcinoma of ovary (ORDO: Orphanet_454723) |
Species of origin |
Homo sapiens (Human)
(NCBI Taxonomy: 9606) |
Hierarchy |
Parent: CVCL_1304 (IGROV-1) |
Sex of cell |
Female |
Age at sampling |
47Y |
Category |
Cancer cell line |
Publications | PubMed=9443634; DOI=10.1007/s002800050727 Ma J.-G., Maliepaard M., Kolker H.J., Verweij J., Schellens J.H.M. Abrogated energy-dependent uptake of cisplatin in a cisplatin-resistant subline of the human ovarian cancer cell line IGROV-1. Cancer Chemother. Pharmacol. 41:186-192(1998) PubMed=9488600; DOI=10.1007/s002800050744 Ma J.-G., Maliepaard M., Nooter K., Boersma A.W.M., Verweij J., Stoter G., Schellens J.H.M. Synergistic cytotoxicity of cisplatin and topotecan or SN-38 in a panel of eight solid-tumor cell lines in vitro. Cancer Chemother. Pharmacol. 41:307-316(1998) PubMed=22792399; DOI=10.1371/journal.pone.0040717; PMCID=PMC3394717 Stordal B., Hamon M., McEneaney V., Roche S., Gillet J.-P., O'Leary J.J., Gottesman M.M., Clynes M. Resistance to paclitaxel in a cisplatin-resistant ovarian cancer cell line is mediated by P-glycoprotein. PLoS ONE 7:E40717-E40717(2012) |
Cross-references |
Cell line databases/resources |
cancercelllines; CVCL_C1M7
|
Encyclopedic resources |
Wikidata; Q114311715
|
Entry history |
Entry creation | 22-Sep-2022 |
Last entry update | 05-Oct-2023 |
Version number | 5 |
---|